Gold bars to be exempt from tariffs, White House clarifies
Investing.com - UBS raised its price target on Biogen (NASDAQ:BIIB) to $130.00 from $119.00 on Monday, while maintaining a Neutral rating on the stock. Currently trading at $133.71, Biogen, a prominent player in the Biotechnology industry with a market cap of $19.6 billion, shows mixed signals from analysts. According to InvestingPro data, analyst targets range from $115 to $260, suggesting significant market uncertainty.
The firm expressed skepticism about the commercial market opportunity for presymptomatic Alzheimer’s disease treatment, despite recent investor optimism surrounding Leqembi.
UBS indicated it remains on the sidelines regarding Biogen stock based on its commercial opportunity review, clinical data assessment, and key opinion leader checks.
The firm specifically noted it "struggles to foresee pre-AD as a tangible market opportunity at this juncture."
UBS has incorporated risk-adjusted sales into its financial model for Biogen, reflecting its cautious stance on the company’s Alzheimer’s disease treatment prospects.
In other recent news, Biogen has announced several developments across its product pipeline and financial outlook. RBC Capital has reiterated its Outperform rating for Biogen with a price target of $208, citing potential acceleration in Leqembi sales next year and promising catalysts from its immunology and inflammation portfolio. Meanwhile, JPMorgan has maintained a Neutral rating with a $175 price target, projecting second-quarter sales of $2.4 billion and earnings per share of $4.02, which aligns with consensus estimates. Biogen has also initiated a Phase 3 trial for felzartamab, targeting primary membranous nephropathy, expecting results in 2029. Furthermore, the company reported positive interim data for its SMA treatment, salanersen, which showed significant improvements in motor function in children. Additionally, Biogen has started a Phase 3 trial for omaveloxolone in children with Friedreich ataxia, aiming to address unmet needs in younger patients. These developments highlight Biogen’s ongoing efforts to expand its treatment portfolio and address various medical conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.